European Union - English - EMA (European Medicines Agency)

theravance biopharma ireland umited - telavancin - pneumonia, bacterial; cross infection - antibacterials for systemic use, - vibativ is indicated for the treatment of adults with nosocomial pneumonia including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant staphylococcus aureus (mrsa).vibativ should be used only in situations where it is known or suspected that other alternatives are not suitable.consideration should be given to official guidance on the appropriate use of antibacterial agents.

United States - English - NLM (National Library of Medicine)

theravance biopharma r&d, inc. - telavancin hydrochloride (unii: 0701472zg0) (telavancin - unii:xk134822z0) - telavancin 15 mg in 1 ml - vibativ is indicated for the treatment of adult patients with complicated skin and skin structure infections (csssi) caused by susceptible isolates of the following gram-positive microorganisms: staphylococcus aureus (including methicillin-susceptible and -resistant isolates), streptococcus pyogenes , streptococcus agalactiae , streptococcus anginosus group (includes s. anginosus, s. intermedius, and s. constellatus) , or enterococcus faecalis (vancomycin-susceptible isolates only). vibativ is indicated for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (habp/vabp), caused by susceptible isolates of staphylococcus aureus (both methicillin-susceptible and -resistant isolates). vibativ should be reserved for use when alternative treatments are not suitable. combination therapy may be clinically indicated if the documented or presumed pathogens include gram-negative organisms. appropriate specimens for bacteriological examination should be obtained in or

United States - English - NLM (National Library of Medicine)

theravance, inc. - telavancin hydrochloride (unii: 0701472zg0) (telavancin - unii:xk134822z0) - telavancin 15 mg in 1 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of vibativ and other antibacterial drugs, vibativ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. combination therapy may be clinically indicated if the documented or presumed pathogens include gram-negative organisms. appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to telavancin. vibativ may be initiated as empiric therapy before results of these tests are known. vibativ is indicated for the treatment of adult patients with complicated skin and skin structure infections (csssi) cause

Israel - English - Ministry of Health

megapharm ltd - telavancin hydrochloride - powder for concentrate for solution for infusion - telavancin hydrochloride 250 mg - telavancin - vibativ is indicated for the treatment of adults with nosocomial pneumonia (np) including ventilator associated pneumonia, known or suspected to be caused by methicillin-resistant staphylococcus aureus (mrsa).vibativ should be used only in situations where it is known or suspected that other alternatives are not suitable.

Israel - English - Ministry of Health

megapharm ltd - telavancin hydrochloride - powder for concentrate for solution for infusion - telavancin hydrochloride 750 mg - telavancin - vibativ is indicated for the treatment of adults with nosocomial pneumonia (np) including ventilator associated pneumonia, known or suspected to be caused by methicillin-resistant staphylococcus aureus (mrsa).vibativ should be used only in situations where it is known or suspected that other alternatives are not suitable.

Singapore - English - HSA (Health Sciences Authority)

mylan pharmaceuticals pte. ltd. - revefenacin - solution - revefenacin 175 mcg /3 ml

Canada - English - Health Canada

pendopharm division of pharmascience inc - telavancin (telavancin hydrochloride) - powder for solution - 250mg - telavancin (telavancin hydrochloride) 250mg - glycopeptides

Canada - English - Health Canada

pendopharm division of pharmascience inc - telavancin (telavancin hydrochloride) - powder for solution - 750mg - telavancin (telavancin hydrochloride) 750mg - glycopeptides

Singapore - English - HSA (Health Sciences Authority)

innomed pte ltd - general & plastic surgery - intended for the treatment of mild to moderate inflammatory acne (including acne vulgaris), comedonal acne and pustular acne for all skin types (fitzpatrick i-vi).

Australia - English - Department of Health (Therapeutic Goods Administration)

huntleigh healthcare pty ltd -